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Focal segmental glomerulosclerosis is a histological pattern on renal biopsy caused by diverse mechanisms. In its primary form,
a circulatory factor is implicated in disease onset and recurrence. The natural history of primary FSGS is unpredictable, since
some patients are unresponsive towards immunosuppressive measures. Immunologic changes, leading to a proinflammatory or
profibrotic milieu, have been implicated in disease progression, namely, glomerular scarring, eventually leading to end-stage renal
disease. Among these, interleukin-1ß, tumor-necrosis factor-𝛼 (TNF-𝛼), and transforming growth factor-ß1 (TGF-ß1) have emerged
as important factors. Translating these findings into clinical practice dampened the enthusiasm, since both TNF-𝛼 and TGF-ß1
blockade failed to achieve significant control of the disease. More recently, a role of the complement system has been demonstrated
which in factmay be another attractive target in clinical practice. Rituximab, blockingCD20-bearing cells, demonstrated conflicting
data regarding efficacy in FSGS. Finally, the T-cell costimulating molecule B7-1 (CD80) is implicated in development of proteinuria
in general. Blockade of this target demonstrated significant benefits in a small cohort of resistant patients. Taken together, this review
focuses on immunology of FSGS, attributable to either the disease or progression, and discusses novel therapeutic approaches
aiming at targeting immunologic factors.
1. Introduction
Primary or idiopathic focal segmental glomerulosclerosis
(FSGS) remains a therapeutic challenge due to its unpre-
dictable disease course. It is assumed to be a lesion rather
than a specific glomerular disease and different lesions have
been described by the Columbia group which may predict
renal outcome of the patients [1]. In primary FSGS one or
more putative circulatory factor(s), yet to be identified, are
implicated in disease occurrence and recurrence. Immuno-
logic changes attributable to primary FSGS have attracted
more attention recently, since targeted therapeutics became
available over the last two decades. The aim of this review is
to focus on immunologic changes described in primary FSGS
and their implication on potential future therapeutic options.
2. T-Cell Involvement in Focal
Segmental Glomerulosclerosis
Early reports hypothesized whether T-cell dysfunction is
implicated to play a role in FSGS or not. In a small cohort of
patients with FSGS, a normal distribution of CD3+, CD4+,
and CD8+ T-cells was found [2]. Another investigation
highlighted abundant expression of CD8+ T-cells, whereas
CD4+ T-cell count was reduced compared to age-matched
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controls [3]. The latter was accompanied by an increase
in interleukin-2R (IL-2R, CD25) expression on CD4+ cells
[3]. CD3-staining of kidney biopsies revealed significantly
higher levels in FSGS compared to minimal change disease
(MCD) or controls. In contrast, FoxP3+ regulatory T-cells
were decreased in FSGS and MCD compared to control
biopsies [4] and may increase once remission is achieved [5].
Restoration of FoxP3+ regulatory T-cells was associated with
regression of nephropathy in a rat model [6].
Circulating Th17 cells as assessed in peripheral blood
mononuclear cells (PBMC) were more abundant in patients
with nephrotic syndrome compared to controls and were
higher in non-MCDpatients. A role for theTh17/interleukin-
17 (IL-17) axis was further supported by the finding that IL-
17 staining was most abundant in FSGS biopsies compared
to MCD and mesangial proliferative glomerulonephritis. In
addition, in vitro studies revealed a time- and dose-related
proapoptotic effect of IL-17 on podocytes [7]. Interleukin-
4 positive T-helper cells (Th2) did not differ between FSGS
and MCD patients, whereas a significantly higher amount
was present in patients with membranous nephropathy. In
contrast, the peripheral Th1/Th2 ratio (IFN-𝛾/IL-4 ratio)
was significantly lower in membranous nephropathy when
compared to the other entities. Proteinuria correlated with
the expression of IL-4 positive cells [8].
3. B7-1 (CD80) and Focal
Segmental Glomerulosclerosis
The observation that podocyte expression of the T-cell
costimulatory molecule B7-1 (CD80) may be induced during
glomerular injury, while being absent in normal kidneys,
promoted further explorations in patients with FSGS. In
a small cohort of patients with either na¨ıve or recurrent
FSGS, positive B7-1 staining was present. In an analysis of
diverse glomerular pathologies, patients with lupus nephritis
showed the strongest glomerular or mesangial B7-1 staining
[9].However, a subsequent study did not confirmany positive
podocyte expression of CD80 in patients with FSGS. Benigni
and colleagues failed to show staining of B7-1 in naı¨ve or
recurrent FSGS [10]. In order to understand the role of B7-
1 in the development of FSGS further studies are required.
4. Complement
The complement system is involved in several glomerular
diseases. Recently,Thurman and colleagues analyzed samples
from patients with FSGS enrolled in a study comparing
efficacy of cyclosporine A (CSA) withmycophenolate mofetil
(MMF). Patients with FSGS had higher levels of plasma
Ba and C4a compared to healthy controls and patients
with antineutrophil cytoplasm antibody- (ANCA-) associ-
ated vasculitis or lupus nephritis or healthy individuals.
UrinaryC4a levelswere highest in FSGSpatients compared to
samples obtained from patients with chronic kidney disease
(CKD), ANCA-associated vasculitis, and lupus nephritis.
Both plasma and urine sC5b-C9 were significantly higher in
patients with FSGS compared to the comparators including
CKD patients. Although number of subgroup analyses is low,
MMF-treated patients showed a significant decline of plasma
sC5b-C9 over time [11].
5. Transforming Growth Factor-ß1
Intrarenal gene expression of transforming growth factor-ß1
(TGF-ß1) revealed a positive predictive value of 90% and a
negative predictive value of 80% to identify FSGS compared
to other examined histologic lesions. Among the cytotoxic
effectors, Fas ligand tended to show coexpression with TGF-
ß1, while granzyme B and perforin were expressed in all
steroid-resistant cases [12]. In line with this observation,
Souto and coworkers showed abundant expression of TGF-ß1
in steroid-resistant cases (majority having FSGS) compared
to controls. Moreover, TGF-ß1 expression was highest in
patients with a relapsing steroid-resistant disease course [13].
In vitro experiments indicated an upregulation of neuropilin-
2 (NRP2) following TGF-ß1 stimulation, which was inversely
correlated with estimated glomerular filtration rate at the
time of biopsy and correlated with subsequent decline in
renal function [14]. This highlights a role of TGF-ß1 in FSGS,
especially in those with a steroid-resistant disease course who
might progress to end-stage renal disease (ESRD).
6. Other Cytokines and Their Role in
Focal Segmental Glomerulosclerosis
Other cytokines, namely, interleukin-1ß (IL-1ß) and
interleukin-6 (IL-6), were elevated in patients with nephrotic
syndrome compared to controls. Renal histopathology
revealed higher IL-1ß expression in FSGS kidney biopsy
specimen compared to MCD or mesangial proliferative
glomerulonephritis [7]. Immunohistochemistry highlighted
a differential regulation of glomerular and tubulointerstitial
expression of tumor-necrosis factor-𝛼 (TNF-𝛼) in MCD
and FSGS. Glomerular staining for TNF-𝛼 expression was
scarce, while tubulointerstitial staining was prominent in
FSGS. This was contrary in patients with MCD. Bakr et
al. reported on children with MCD and FSGS. TNF-𝛼
levels were significantly higher in patients with active
nephrotic syndrome and correlated with the degree of
proteinuria. Moreover, positive correlation between TNF-𝛼
production and the degree of mesangial hypercellularity and
glomerulosclerosis was reported. A TNF-𝛼 level of greater
than or equal to a cut-off of 50 pg/mL was able to predict
resistance towards steroids in these patients (predictability
93.2%) [15].
Interleukin-10 (IL-10) levels were almost identical in
both entities and increased during nephrotic-range pro-
teinuria. The authors speculated that IL-10 is increasing
with the amount of protein loss, whereas TNF-𝛼 in the
tubulointerstitiummay reflect interstitial fibrosis [16]. Serum
interleukin-12 (IL-12) was not detectable in the majority of
patients with FSGS [17]. Niemir and coworkers observed
differential expression in preserved glomeruli compared to
sclerotic ones. Whereas IL-1𝛼/ß, IL-1 RII, and IL-1 receptor
antagonist (RA) were similarly distributed in nonsclerotic
glomeruli of patients with FSGS, glomerulosclerosis was
accompanied by a scarce expression of IL-1ß and IL-1 RII
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only [18]. Analysis of urinary cytokine excretion revealed
significantly higher levels of interleukin-2 (IL-2), interleukin-
4 (IL-4), IL-6, IL-10, interferon-𝛾 (IFN-𝛾), and monocyte
chemoattractant protein-1 (MCP-1) in a subgroup of patients
with MCD/FSGS, whereas interleukin-17A (IL-17A), TNF-
𝛼, and TGF-ß1 were unaltered compared to a control group
[19]. Urinary excretion of interleukin-18 (IL-18)/CXCL8,
MCP-1/CCL2, and RANTES/CCL5 was not different in an
analysis of patients with steroid-resistant or steroid-sensitive
nephrotic syndrome. However, there was an association
between IL-18/CXCL8 expression and degree of proteinuria
[13].
7. Macrophages, HLA, and
Myeloid-Derived Suppressor Cells in
Focal Segmental Glomerulosclerosis
Interstitial staining forCD68 implicated a significantly higher
number of macrophages in childhood FSGS compared to
MCD or control biopsy specimens. Patients with a steroid-
resistant course had higher numbers compared to steroid-
dependent or frequently relapsing patients [4]. Examination
of human leukocyte antigen (HLA) by immunohistochem-
istry indicated that the HLA-DR antigen was present in all
patients in glomerular endothelial cells, whereas positivity
was present in one quarter in extraglomerular mesangium
cells and podocytes [20]. Reduction of diverse HLA class II
antigens, namely, −DQ, −DR, −DP, and –DY, was observed
in sclerotic glomeruli of patients with FSGS in comparison to
healthy kidney tissue [21]. Myeloid-derived suppressor cells
(MDSC), characterised by CD11b+HLA-DR-CD14-CD15+
staining, in peripheral blood increased following initiation
of steroids in responsive FSGS subjects, whereas no increase
was found in steroid-resistant patients. Induction of MDSC
was capable of suppressing T-cell proliferation and induced
regulatory T-cells in vitro [22].
8. B-Cells and Focal
Segmental Glomerulosclerosis
Glomerular staining for CD20 positivity was significantly and
numerically higher in FSGS compared to controls and MCD,
respectively. In contrast, interstitial staining was reduced
in FSGS and MCD in comparison to control biopsies [4].
Strassheim and coworkers examined the effect of anti-CD20
treatment and prevention of IgM deposition in a mouse
model of FSGS. Approximately 30% of the kidney biop-
sies examined displayed glomerular IgM deposition, either
colocalized with C3 or not. This subgroup may be more
susceptible towards a B-cell depleting therapy as shown in
their Adriamycin-induced nephropathy [23].
9. Transition into Clinical Practice:
Towards Tailored Medicine in Focal
Segmental Glomerulosclerosis
9.1. Abatacept. Yu and coworkers demonstrated efficacy of
B7-1 blockade with abatacept (CTLA-Ig) in rituximab- and
steroid-resistant cases [9]. Mechanistically, they found that
abatacept was capable of blocking ß1-integrin activation.
Although these data suggest clinical benefit based on mecha-
nistic insights, the initial enthusiasmwas seriously dampened
by subsequent reports. Proteinuria remained unchanged in
one patient with primary and three patients with recurrent
FSGS receiving either abatacept or belatacept, the latter
having predominant effects on B7-2 (CD86) [24]. Although
kidney biopsies from patients with lupus nephritis showed
strong B7-1 staining [9, 25], a recent trial comparing abatacept
as add-on therapy to cyclophosphamide to a standard-of-
care treated control group showed no improvement with the
addition of abatacept, again disproving a role of B7-1 blockade
in proteinuric kidney diseases [26].
9.2. Adalimumab. As demonstrated above, TNF-𝛼 is a
promising target in patients with FSGS. Thus, adalimumab,
a human monoclonal antibody targeting TNF-𝛼, was tested
in a phase I trial including 10 patients with resistant FSGS.
Pharmacokinetics revealed an increased clearance by 160%
compared to healthy controls and patients with rheumatoid
arthritis [27] which was attributable to renal and nonrenal
clearance with a direct impact of proteinuria on the former
finding [28]. While two patients had a partial remission
during follow-up time (proteinuria decreased from a PCR of
initially 3.6 and 17mg/mg creatinine to 0.6 in both subjects),
the other eight patients remained nephrotic [27]. Moreover,
the authors demonstrated a stabilization of the estimated
glomerular filtration rate during follow-up in some patients
[29]. A subsequent phase II trial in resistant FSGS failed to
recruit significant numbers. Of the seven included patients,
no patient had a significant response with worsening of
proteinuria in 4/6 patients [30]. Although small numbers
limit definite conclusions, a general recommendation related
to adalimumab use in resistant FSGS is not warranted.
9.3. Fresolimumab. TGF-ß is implicated in several mecha-
nisms leading to pathologic glomerular changes. Targeting
this pivotal cytokine with a human monoclonal antibody,
namely, fresolimumab, led to an estimated glomerular fil-
tration rate decline of 5.9mL/min (annualized 19mL/min),
whereas mean proteinuria measured as PCR decreased by
1.2mg/mg creatinine in a phase I trial [31]. A further multi-
national trial investigating the efficacy of this substance has
already completed recruitment.
9.4. Rituximab. Although experience of rituximab’s use in
FSGS is limited to case reports or series, it is widely used
to treat resistant cases [32]. Analysis of the Spanish Group
for the Study of Glomerular Diseases (GLOSEN) revealed
that two patients had a clear and sustained improvement
following rituximab treatment, while one patient had a
transient response twice and the other five patients did not
respond to the treatment [33]. In our analysis including
relapsing patientsmost patients achieved sustained remission
with a reduction of relapses following rituximab. However,
one patient showed no response following rituximab therapy
[34]. This is in line with a recent analysis of childhood onset
steroid-resistant and congenital nephrotic syndrome, which
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showed equivalent response rates of rituximab compared to
calcineurin inhibitors, with 40–45% of the patients achieving
complete remission [35]. Treatment with rituximab might
lead to life-threatening infections as reported in ANCA-
associated vasculitis, for example [36].No such complications
have been reported in adult patients with FSGS treated with
rituximab so far. Thus, it might be an option in difficult-to-
treat FSGS [37]. One potential para-CD20 effect of rituximab
may in fact be stabilization of the actin cytoskeleton. Ritux-
imab partially prevented sphingomyelin phosphodiesterase
acid-like 3b (SMPDL-3b) downregulation and prevented
disruption of the actin cytoskeleton along with apoptosis of
podocytes induced by FSGS sera [38].
10. Conclusions
Several immunologic changes have been identified during
the last decades in FSGS. However, lack of replication or
failure of translation into useful therapeutic measures limits
these findings. With improved laboratory techniques novel
potential targets will be elucidated in the future and hopefully
therapeutic concepts targeting specific molecules, such as
rituximab’s effects on SMPDL-3b, will emerge. Overall, the
aim has to be identification of the responsible pathogenic
factor(s), which may in fact be a useful marker as has been
shown in idiopathic membranous nephropathy.
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